Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefteram pivoxil is an orally active, third-generation cephalosporin antibiotic. It is a prodrug that is rapidly hydrolyzed to its active form, cefteram, following oral administration. The drug works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), which prevents the cross-linking of peptidoglycan layers essential for bacterial structural integrity. It exhibits a broad spectrum of activity against Gram-positive and Gram-negative pathogens, including *Streptococcus pneumoniae*, *Haemophilus influenzae*, and various members of the Enterobacteriaceae family. It is primarily indicated for respiratory, urinary, and skin infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefteram pivoxil.